LYRA
Lyra Therapeutics, Inc.
Biotechnology
Market Cap$781K
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LYRA vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-56.7%
LYRA vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LYRA | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $781K | $1712.35T |
| Revenue (TTM) | $600K | $0.00 |
| Net Income (TTM) | $-33M | $-168M |
| Gross Margin | 50.0% | — |
| Operating Margin | -58.2% | — |
| Total Debt | $34M | $22M |
| Cash & Equiv. | $41M | $194M |
LYRA vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LYRA
DBVT
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Lyra Therapeutics, … (LYRA) | 100 | 0.1 | -99.9% |
| DBV Technologies S.… (DBVT) | 100 | 43.3 | -56.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LYRA vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LYRA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
LYRA
Lyra Therapeutics, Inc.
The Income Pick
LYRA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.65
- Rev growth -1.5%, EPS growth -13.5%, 3Y rev CAGR 75.3%
- Lower volatility, beta 0.65, current ratio 3.41x
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT is the clearest fit if your priority is long-term compounding.
- -87.0% 10Y total return vs LYRA's -100.0%
- 0.3% margin vs LYRA's -54.9%
- +110.4% vs LYRA's -91.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LYRA | -1.5% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs LYRA's -54.9% |
| Stability / Safety | LYRA | Beta 0.65 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs LYRA's -91.6% |
| Efficiency (ROA) | LYRA | -60.2% ROA vs DBVT's -89.0% |
LYRA vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGLYRA
LYRALyra Therapeutics, In…
0leads
DBVTDBV Technologies S.A.
4leads
6 Total Categories
CATEGORYLEADERvs LYRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LYRA and DBVT operate at a comparable scale, with $600,000 and $0 in trailing revenue.
| Metric | LYRALyra Therapeutics… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $600,000 | $0 |
| EBITDAEarnings before interest/tax | -$34M | -$112M |
| Net IncomeAfter-tax profit | -$33M | -$168M |
| Free Cash FlowCash after capex | -$34M | -$151M |
| Gross MarginGross profit ÷ Revenue | +50.0% | — |
| Operating MarginEBIT ÷ Revenue | -58.2% | — |
| Net MarginNet income ÷ Revenue | -54.9% | — |
| FCF MarginFCF ÷ Revenue | -56.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -87.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -17.8% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | LYRALyra Therapeutics… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $781,126 | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | -$5M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -0.31x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.51x | — |
| Price / BookPrice ÷ Book value/share | 2.47x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
DBVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
DBVT leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
DBVT delivers a -130.2% return on equity — every $100 of shareholder capital generates $-130 in annual profit, vs $-10 for LYRA. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to LYRA's 2.97x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs LYRA's 2/9, reflecting mixed financial health.
| Metric | LYRALyra Therapeutics… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -10.3% | -130.2% |
| ROA (TTM)Return on assets | -60.2% | -89.0% |
| ROICReturn on invested capital | -145.5% | — |
| ROCEReturn on capital employed | -109.0% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 2.97x | 0.13x |
| Net DebtTotal debt minus cash | -$6M | -$172M |
| Cash & Equiv.Liquid assets | $41M | $194M |
| Total DebtShort + long-term debt | $34M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
DBVT leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $10 for LYRA. Over the past 12 months, DBVT leads with a +110.4% total return vs LYRA's -91.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs LYRA's -85.0% — a key indicator of consistent wealth creation.
| Metric | LYRALyra Therapeutics… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -86.1% | +4.9% |
| 1-Year ReturnPast 12 months | -91.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | -99.7% | +19.7% |
| 5-Year ReturnCumulative with dividends | -99.9% | -69.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -85.0% | +6.2% |
DBVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LYRA and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
LYRA is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs LYRA's 1.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LYRALyra Therapeutics… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 1.26x |
| 52-Week HighHighest price in past year | $37.50 | $26.18 |
| 52-Week LowLowest price in past year | $0.44 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +1.2% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 22.3 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 159K | 252K |
Evenly matched — LYRA and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LYRALyra Therapeutics… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallDBV Technologies S.A. (DBVT)Leads 4 of 6 categories
Loading custom metrics...
LYRA vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LYRA or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LYRA or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -99. 9% for Lyra Therapeutics, Inc. (LYRA). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LYRA or DBVT?
By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.
(LYRA) is the lower-risk stock at 0. 65β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 95% more volatile than LYRA relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — LYRA or DBVT?
On earnings-per-share growth, the picture is similar: Lyra Therapeutics, Inc.
grew EPS -13. 5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LYRA or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -60. 9% for Lyra Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -62. 8% for LYRA. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LYRA or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LYRA or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Lyra Therapeutics, Inc.
(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). Both have compounded well over 10 years (LYRA: -100. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LYRA and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.